康方生物-B(09926.HK)公佈中期業績 收到AK107里程碑付款 研發開支大增134%
格隆匯8月31日丨康方生物-B(09926.HK)公吿，截至2021年6月30日止六個月，公司收入為人民幣1.29億元，來自收到與對外授權產品AK107有關的里程碑付款。其他收入及收益淨額由截至2020年6月30日止六個月的人民幣4100萬元增加人民幣2410萬元至人民幣6510萬元，主要是由於首次公開發售及2021年1月新股份配售所得款項賺取的利息及當地政府對研發活動的補助增加。
期間研發開支增加134%至截至2021年6月30日止六個月的人民幣5.64億元，主要是由於(i)公司10個內部開發候選藥物的臨牀試驗發展，尤其是兩個雙特異性抗體AK104及AK112均取得令人鼓舞的進展；及(ii)研發人員人數由377名僱員進一步擴大至836名僱員，且僱員薪金增加，令員工成本增加。
公司於報吿期間後繼續在藥物管線及業務運營方面取得重大進展。截至本公吿日期，公司分別有4、28及9項臨牀計劃正在進行Ia、Ib/II及關鍵╱III期研究，並獲得16項IND批准。
為全面支持公司的持續增長，公司將繼續投資於吸引和留住頂尖人才方面，旨在擴大公司的人才庫，並增強公司在臨牀開發和商業化等各個方面的能力。我們的團隊於2021年上半年持續擴張，由2020年12月31日的746名僱員增加至2021年6月30日的1,202名僱員。
公司表示，我們將加快提交新藥監管審評及批准，加速產業化和商業化的籌備以及全球開發計劃，並將繼續在中國和全球（包括美國）迅速推進公司正在進行及計劃中的管道產品臨牀試驗和準備管道產品的商業化。
目前公司處於關鍵性╱III期臨牀階段的研究項目共計9項，處於Ib/II期臨牀階段的研究共有28項。隨着臨牀研究項目數量的增加，公司在資源配置策略上將更加聚焦重點藥物的重要適應症研究項目，以期更加高效推進臨牀計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
